FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.
No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.
For Oak this represents around a 6x return on its 2007 investment, when it paid around $67 million to acquire an equity stake from Baird (which retained part of its position).
PharMEDium is a Lake Forrest, Ill.–based provider of hospital pharmacy sterile compounding services.
Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com
|How Zuck met Oculus: Facebook's big bet on virtual reality|
|Fears grow over China property flameout|
|Oklahoma bans local minimum wage increases|
|China GDP slows to 7.4% in first quarter|
|Researchers claim to hack fingerprint sensor on Samsung's new Galaxy S5|